Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
Adcetris falls victim to NICE’s Cancer Drugs Fund clear-outMore CDF legacy products likely to face same fate Share XAdcetris falls victim to NICE’s Cancer Drugs Fund clear-outhttps://pharmaphorum.com/news/adcetris-falls-victim-nices-cancer-drugs-fund-clear/